Eugenio Gaudio

4PUBLICATIONS
42CO-AUTHORS
Molecular targetsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jun 20, 2025
Novel Flavonoid Derivatives Show Potent Efficacy in Human Lymphoma Models.

Eugenio Gaudio, Paulina Biniecka, Alberto J Arribas

|Feb 07, 2024
ADCT-602, a Novel PBD Dimer-containing Antibody-Drug Conjugate for Treating CD22-positive Hematologic Malignancies.

Francesca Zammarchi, Karin E Havenith, Nikoleta Sachini

|Dec 05, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.

Alberto J Arribas, Sara Napoli, Luciano Cascione

|Nov 28, 2023
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.

Alberto J Arribas, Eugenio Gaudio, Sara Napoli

Pageof 1

Frequent Collaborators

4 joint publications

Francesco Bertoni

3 joint publications

Chiara Tarantelli

3 joint publications

Luciano Cascione

2 joint publications

Alberto J Arribas